Equities analysts expect OncoSec Medical Inc (NASDAQ:ONCS) to report earnings of ($0.18) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for OncoSec Medical’s earnings. OncoSec Medical reported earnings of ($0.28) per share during the same quarter last year, which indicates a positive year over year growth rate of 35.7%. The firm is scheduled to report its next quarterly earnings results on Wednesday, October 24th.
According to Zacks, analysts expect that OncoSec Medical will report full-year earnings of ($0.93) per share for the current fiscal year, with EPS estimates ranging from ($0.95) to ($0.90). For the next year, analysts expect that the firm will post earnings of ($0.70) per share, with EPS estimates ranging from ($0.81) to ($0.60). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for OncoSec Medical.
OncoSec Medical (NASDAQ:ONCS) last released its quarterly earnings data on Wednesday, June 13th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.04).
In related news, CFO Richard B. Slansky sold 84,984 shares of OncoSec Medical stock in a transaction on Thursday, July 5th. The shares were sold at an average price of $1.39, for a total value of $118,127.76. Following the transaction, the chief financial officer now owns 255,000 shares in the company, valued at approximately $354,450. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Punit Dhillon sold 28,145 shares of OncoSec Medical stock in a transaction on Monday, June 18th. The stock was sold at an average price of $1.39, for a total transaction of $39,121.55. Following the completion of the transaction, the director now owns 355,702 shares in the company, valued at approximately $494,425.78. The disclosure for this sale can be found here. Insiders sold a total of 300,106 shares of company stock worth $419,658 in the last quarter. Insiders own 5.50% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Millennium Management LLC increased its holdings in shares of OncoSec Medical by 19.5% during the 2nd quarter. Millennium Management LLC now owns 1,195,315 shares of the biotechnology company’s stock worth $1,650,000 after purchasing an additional 194,739 shares during the period. Nexthera Capital LP increased its holdings in shares of OncoSec Medical by 26.6% during the 2nd quarter. Nexthera Capital LP now owns 2,614,297 shares of the biotechnology company’s stock worth $3,608,000 after purchasing an additional 550,000 shares during the period. DRW Securities LLC increased its holdings in shares of OncoSec Medical by 157.1% during the 2nd quarter. DRW Securities LLC now owns 180,000 shares of the biotechnology company’s stock worth $248,000 after purchasing an additional 110,000 shares during the period. BlackRock Inc. increased its holdings in shares of OncoSec Medical by 1,303.5% during the 2nd quarter. BlackRock Inc. now owns 238,940 shares of the biotechnology company’s stock worth $330,000 after purchasing an additional 221,916 shares during the period. Finally, Point72 Asset Management L.P. increased its holdings in shares of OncoSec Medical by 47.5% during the 1st quarter. Point72 Asset Management L.P. now owns 3,215,000 shares of the biotechnology company’s stock worth $6,044,000 after purchasing an additional 1,035,000 shares during the period. Hedge funds and other institutional investors own 26.16% of the company’s stock.
Shares of ONCS stock traded down $0.06 on Wednesday, hitting $1.41. The company’s stock had a trading volume of 534,160 shares, compared to its average volume of 597,358. OncoSec Medical has a fifty-two week low of $0.90 and a fifty-two week high of $2.95. The firm has a market cap of $76.95 million, a PE ratio of -1.33 and a beta of 2.90.
About OncoSec Medical
OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.
Further Reading: Are Wall Street analysts’ stock ratings worth following?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.